+

WO2002100350A3 - Dopamine receptor ligands and therapeutic methods based thereon - Google Patents

Dopamine receptor ligands and therapeutic methods based thereon Download PDF

Info

Publication number
WO2002100350A3
WO2002100350A3 PCT/US2002/018914 US0218914W WO02100350A3 WO 2002100350 A3 WO2002100350 A3 WO 2002100350A3 US 0218914 W US0218914 W US 0218914W WO 02100350 A3 WO02100350 A3 WO 02100350A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic methods
methods based
receptor ligands
dopamine receptor
compounds
Prior art date
Application number
PCT/US2002/018914
Other languages
French (fr)
Other versions
WO2002100350A2 (en
Inventor
Shaomeng Wang
Judith Varady
Xihan Wu
Ji Min
Ke Ding
Beth Levant
Original Assignee
Univ Michigan
Shaomeng Wang
Judith Varady
Xihan Wu
Ji Min
Ke Ding
Beth Levant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Shaomeng Wang, Judith Varady, Xihan Wu, Ji Min, Ke Ding, Beth Levant filed Critical Univ Michigan
Priority to EP02744349A priority Critical patent/EP1406631A4/en
Priority to AU2002345707A priority patent/AU2002345707A1/en
Priority to CA002450315A priority patent/CA2450315A1/en
Priority to JP2003503176A priority patent/JP2005517630A/en
Publication of WO2002100350A2 publication Critical patent/WO2002100350A2/en
Publication of WO2002100350A3 publication Critical patent/WO2002100350A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compounds designed as ligands (e.g., agonists, antagonists, and partial agonists) for dopamine receptors (e.g., D1, D2, D3, D4, and D5), and in particular, the D1, D2, and D3 dopamine receptors. The present invention also relates to methods for rationally designing these compounds and to therapeutic methods of using these compounds.
PCT/US2002/018914 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon WO2002100350A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02744349A EP1406631A4 (en) 2001-06-13 2002-06-13 DOPAMINE RECEPTOR LIGANDS AND CORRESPONDING THERAPEUTIC METHODS
AU2002345707A AU2002345707A1 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon
CA002450315A CA2450315A1 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon
JP2003503176A JP2005517630A (en) 2001-06-13 2002-06-13 Dopamine receptor ligand and therapeutic method based thereon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29744501P 2001-06-13 2001-06-13
US60/297,445 2001-06-13

Publications (2)

Publication Number Publication Date
WO2002100350A2 WO2002100350A2 (en) 2002-12-19
WO2002100350A3 true WO2002100350A3 (en) 2003-05-22

Family

ID=23146337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018914 WO2002100350A2 (en) 2001-06-13 2002-06-13 Dopamine receptor ligands and therapeutic methods based thereon

Country Status (3)

Country Link
EP (1) EP1406631A4 (en)
CA (1) CA2450315A1 (en)
WO (1) WO2002100350A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10226459A1 (en) * 2002-06-13 2004-01-08 Neurobiotec Gmbh Use of dopamine partial agonists to treat restless legs syndrome
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US7538112B2 (en) 2004-05-07 2009-05-26 Merck & Co., Inc. HIV integrase inhibitors
BRPI0916241A2 (en) * 2008-07-16 2017-06-27 Richter Gedeon Nyrt pharmaceutical formulations containing dopamine receptor binders
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JP5791595B2 (en) 2009-05-22 2015-10-07 アッヴィ・インコーポレイテッド Modulator of 5-HT receptor and method of use thereof
RU2567751C2 (en) 2010-05-21 2015-11-10 Эббви Инк. Tricyclic pyrrole derivatives useful as 5-ht receptor modulators
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
ES2950507T3 (en) 2015-08-19 2023-10-10 Univ East Carolina Treatment and management of increased restless legs syndrome
CN105418605B (en) * 2015-11-23 2017-12-22 东南大学 A kind of preparation method of improved nitrogenous tricyclic antidepressants dopamine D 3 receptor part
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498849A (en) * 1966-10-05 1970-11-15 Ciba Geigy Pyrazino 1 2-a quinolines having adrenolytic sedative and antihyperten - sive activity
WO1996023789A1 (en) * 1995-02-03 1996-08-08 Sankyo Company, Limited Hexahydropyrazinoquinoline derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647791A (en) * 1967-09-19 1972-03-07 Ciba Geigy Corp 2 3 4 4a 5 6-hexahydro - 1h - pyrazino (1 2-a) quinolines and pharmaceutical compositions containing same
BR9406128A (en) * 1993-03-01 1996-02-27 Merck Sharp & Dohme Use of a process compound for the treatment and / or prevention of psychotic disorders compound pharmaceutical composition processes for the preparation of a compound and a pharmaceutical composition
EP0775118B1 (en) * 1994-08-05 2003-06-04 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
US5688950A (en) * 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498849A (en) * 1966-10-05 1970-11-15 Ciba Geigy Pyrazino 1 2-a quinolines having adrenolytic sedative and antihyperten - sive activity
WO1996023789A1 (en) * 1995-02-03 1996-08-08 Sankyo Company, Limited Hexahydropyrazinoquinoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SAXENA ET AL.: "QSAR in a series of hypotensive 3-substituted 2,3,4,,4a,5,6-hexahydro-1(H)-pyrazino(1,2-a)quinolines", INDIAN JOURNAL OF CHEMISTRY, vol. 19B, no. 10, October 1980 (1980-10-01), pages 879 - 881, XP002961252 *
See also references of EP1406631A4 *

Also Published As

Publication number Publication date
EP1406631A4 (en) 2005-03-23
WO2002100350A2 (en) 2002-12-19
EP1406631A2 (en) 2004-04-14
CA2450315A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
IL182090A (en) 2,6-substituted-4-monosubstituted amino-pyrimidines as prostaglandin d2 receptor antagonists
AP2006003566A0 (en) Muscarinic Acetycholine receptor antagonists.
WO2006026759A3 (en) Humanized anti-beta7 antagonists and uses therefor
HK1091403A1 (en) 5-ht 1a receptor subtype agonist
PL376373A1 (en) Selected cgrp antagonists, method for production and use thereof as medicament
AU2003238597A1 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
SI1506190T1 (en) (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
WO2002100350A3 (en) Dopamine receptor ligands and therapeutic methods based thereon
EP1551833A4 (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine
HUE037069T2 (en) Process for the preparation of highly pure 2,4'-methylenediphenyldiisocyanate
DK1440059T3 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
PL378023A1 (en) Mercaptoimidazoles as ccr2 receptor antagonists
PL372463A1 (en) Thiazole derivatives as npy receptor antagonists
WO2005060947A3 (en) Agonist and antagonist ligands of the nociceptin receptor
PL370799A1 (en) Aminotetralin derivatives as muscarinic receptor antagonists
GB0203412D0 (en) 5-HT 2B receptor antagonists
HK1077827A1 (en) Diazabicyclononane and-decane derivatives their use as opioid receptor ligands
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
WO2007039606A3 (en) Insulin receptor antagonists and related compositions, uses and methods
WO2004067093A3 (en) Nk1 receptor antagonists for the treatment of functional dyspepsia
AU2002258506A1 (en) Dopamine d4 receptor antagonists as treatment for attention deficit-hyperactivity disorder
IL158063A0 (en) Crf receptor antagonists
AU2003284212A8 (en) Process for the preparation of (s,s)-cis-2-phenyl-3-aminopiperidine
ITVR20020030A0 (en) MIXTURE FOR WELDING POWDER, AS WELL AS PROCEDURE FOR THE USE OF SAID MIXTURE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2450315

Country of ref document: CA

Ref document number: 2003503176

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002744349

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002744349

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载